8-K: HeartSciences Secures $3M Debt Financing with Streeterville

HeartSciences Inc. has entered into an unsecured promissory note agreement with Streeterville Capital, LLC for $3 million in gross proceeds, carrying a 12% interest rate and an 18-month maturity.

Summary

• HeartSciences Inc. (the Company) entered a Note Purchase Agreement with Streeterville Capital, LLC on January 13, 2026.
• Streeterville Capital purchased an unsecured promissory note with an original principal amount of $3,605,000.
• The note included an original issue discount (OID) of $600,000 and reimbursed Streeterville's transaction expenses of $5,000.
• The gross proceeds received by the Company from this transaction were $3,000,000.
• The note bears interest at a rate of 12% per annum, compounded daily, and matures 18 months after its issuance date.
• Streeterville Capital has the right to require the Company to redeem a portion of the note, not exceeding $405,000 per month, starting six months after issuance.
• If the Company has not reduced the outstanding balance by at least $1,250,000 by the 12-month anniversary, the outstanding balance will automatically increase by 5%.
• The Company may prepay all or any portion of the outstanding balance at any time.
• The agreement includes customary affirmative and restrictive covenants, representations, warranties, and events of default.
• Upon certain events of default, the outstanding balance becomes immediately due and payable, and the interest rate automatically increases to 18% per annum or the maximum rate permitted by law.
• The note was issued in reliance on the private placement exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506.

Sentiment

Score: 3

Explanation: The filing indicates a successful capital raise, which is positive for immediate liquidity. However, the terms of the debt, including a significant original issue discount, high interest rate, potential for monthly redemptions, and punitive clauses for non-performance, are highly unfavorable and suggest financial strain or limited access to more conventional financing. The restrictive covenants also limit future financing flexibility. This points to a challenging financial position for the company.

Positives

• Secured $3,000,000 in gross proceeds to support operations and strategic initiatives.
• The Company retains the option to prepay the note at any time, offering flexibility in managing its debt obligations.

Negatives

• The effective cost of capital is high due to a $600,000 original issue discount and $5,000 in transaction expenses on a $3,605,000 note, resulting in only $3,000,000 in net proceeds.
• The note carries a high annual interest rate of 12%, compounding daily, which increases the overall cost of borrowing.
• Streeterville Capital has the right to demand monthly redemptions of up to $405,000, potentially creating liquidity pressure on the Company.
• A 5% automatic increase in the outstanding balance will occur if the Company fails to reduce the balance by at least $1,250,000 within 12 months, adding to the debt burden.
• Upon an event of default, the interest rate escalates to 18% per annum, significantly increasing the cost of non-compliance.
• The Company is restricted from making "Restricted Issuances" (certain types of debt or equity with variable conversion/exercise prices or reset features) without Streeterville's prior written consent, limiting future financing options.
• Mandatory prepayments of 20% of gross proceeds from future fundraising transactions (including those from existing agreements after an event of default) could divert capital from other uses.

Risks

• **Liquidity Risk**: Streeterville Capital's right to demand monthly redemptions of up to $405,000 could strain the Company's cash flow and liquidity.
• **Default Risk**: Failure to meet payment obligations, observe covenants, or the occurrence of a "Fundamental Transaction" without consent could trigger an Event of Default, leading to immediate acceleration of the note at an increased interest rate of 18%.
• **Dilution Risk (Indirect)**: Restrictions on "Restricted Issuances" could limit the Company's ability to raise equity or convertible debt on favorable terms in the future, potentially forcing reliance on more expensive or dilutive financing methods if capital is needed.
• **Increased Debt Burden**: The automatic 5% increase in the outstanding balance if a $1,250,000 reduction target is not met within 12 months adds to the principal amount owed.
• **Operational Restrictions**: Covenants in the Note Purchase Agreement and Note may impose restrictions on the Company's operations or strategic flexibility, such as requiring timely SEC filings and maintaining NASDAQ listing.
• **Legal and Arbitration Costs**: The agreement specifies binding arbitration in Utah and includes provisions for the losing party to pay all costs and reasonable attorneys' fees in disputes, potentially increasing legal expenses.
• **Fundamental Transaction Risk**: A "Fundamental Transaction" (e.g., merger, sale of assets, change of control) without Streeterville's consent or full repayment of the note could trigger an Event of Default and allow Streeterville to seek injunctive relief to prevent the transaction.

Future Outlook

The Company has secured short-term financing to support its operations, but the terms of the note, including potential monthly redemptions and a balance increase clause, suggest a need for significant cash flow generation or further capital raises within the next 12-18 months to manage this debt effectively. The restrictions on future financing types ("Restricted Issuances") may influence the Company's strategic options for long-term capital.

Industry Context

This type of high-cost, short-term debt financing, often involving original issue discounts and restrictive covenants, is common for smaller, growth-stage companies, particularly in the medical device or biotech sectors, that may have limited access to traditional bank lending or more favorable equity markets. It indicates a need for immediate capital and can be a bridge to future, more substantial financing rounds or revenue generation. The terms reflect the perceived risk profile of the borrower and the current market conditions for such financing.

Comparison to Industry Standards

• The 12% annual interest rate and 18% default interest rate are significantly higher than typical corporate bond yields for investment-grade companies (e.g., large pharmaceutical companies like Johnson & Johnson or Medtronic might see rates below 5%).
• The $600,000 OID on a $3,605,000 note (approximately 16.6% discount) is substantial, indicating a high cost of capital often seen in distressed debt or for companies with limited alternative financing options. For comparison, a typical corporate bond issuance for a healthy company would have a much smaller, if any, OID.
• The monthly redemption option for the lender (Streeterville Capital) of up to $405,000 is an aggressive feature, placing significant liquidity demands on HeartSciences Inc. This is not a standard feature in traditional corporate loans and is more akin to certain types of structured debt or death spiral financing, though not explicitly convertible here.
• The 5% automatic increase in outstanding balance if a $1.25 million reduction target is not met within 12 months is a punitive clause, reflecting the lender's strong position and risk mitigation strategy, which is atypical for standard corporate debt.
• The "Restricted Issuance" covenants are common in venture debt or other specialized financing to protect the lender's position from potentially dilutive or unfavorable future capital raises, but they can constrain a company's strategic flexibility compared to companies with more open capital structures.

Stakeholder Impact

• **Shareholders**: The high cost of this debt and the restrictive covenants could negatively impact shareholder value by increasing financial risk, potentially limiting future growth opportunities, and making future equity raises more challenging or dilutive. The mandatory prepayment clause on future fundraising could also reduce net proceeds available for company growth.
• **Creditors**: Streeterville Capital, as the lender, benefits from strong protections, including high interest rates, default penalties, and specific performance rights, which enhance its position relative to other potential creditors.
• **Employees/Customers/Suppliers**: The immediate capital infusion provides short-term stability, which could be positive for ongoing operations, but the long-term financial burden and restrictions could create uncertainty if not managed effectively.

Next Steps

• Manage cash flow to meet potential monthly redemption demands of up to $405,000 starting July 13, 2026.
• Work to reduce the outstanding balance by at least $1,250,000 by January 13, 2027, to avoid a 5% automatic increase in the note's balance.
• Ensure timely filing of all SEC reports and maintenance of NASDAQ listing as per covenants.
• Carefully consider the implications of "Restricted Issuances" and "Fundamental Transactions" on future strategic decisions.

Key Dates

Recommendation

While the company secured $3 million in capital, the terms of the debt are highly unfavorable, indicating significant financial distress or limited access to conventional financing. The substantial original issue discount, high 12% interest rate (escalating to 18% on default), and the lender's right to demand monthly redemptions of up to $405,000 create immense liquidity pressure. Furthermore, the 5% automatic balance increase if a $1.25 million reduction target is missed within 12 months, along with restrictive covenants on future capital raises, severely constrains the company's financial flexibility and increases its risk profile. These terms suggest a high probability of future financial strain, potential dilution, or further costly financing, making the stock a high-risk investment with significant downside potential.

Keywords

HeartSciences Inc., HSCS, Streeterville Capital, Promissory Note, Debt Financing, Unsecured Debt, Original Issue Discount, OID, SEC Filing, Form 8-K, Corporate Finance, Private Placement, Accredited Investor, Corporate Governance, Risk Management